Exane BNP Paribas Ups GSK To Outperform

Lisa Levin , Benzinga Staff Writer

February 14, 2011 6:04am Comments

Analysts at Exane BNP Paribas upgrade GlaxoSmithKline plc (NYSE: GSK) from “neutral” to “outperform.”

GSK shares fell 1.00% to close at $37.75 on Friday.

Posted-In: Exane BNP Paribas Upgrades Analyst Ratings

Need analyst data?
Click here to see licensing options.

Stock	Firm	Action	PT
SEDG	B of A Securities	Maintains	411.0
PTLO	Piper Sandler	Maintains	28.0
AOUT	Lake Street	Maintains	26.0
RAPT	Piper Sandler	Maintains	52.0
OCX	Lake Street	Maintains	6.0

1	LLY: Eli Lilly Co. Q2 FY2025 Earnings Transcript
2	WLDN, COLL: Earnings Scheduled For August 7, 2025
3	CVNA, AMZN: Carvana CEO Ernest Garcia, VP General Counsel Paul Breaux...
4	TMUS: Here's How Much $1000 Invested In T-Mobile US 10...
5	LLY, NVO: Eli Lilly's Closely Watched Obesity Pill...
6	XYZ, UBER: Nasdaq Surges Over 1% Amid Jump In A...
7	CNQ, $BTC: Apple Jumps, Eli Lilly Cras...

1	LYV: Here's How Much You Would Have Made Owning Live Nation Entertainment Sto...
2	LZMH, GIBO: 12 Communication Services Stocks Moving In Friday's After-Mark...
3	CLDI, SINT: 12 Health Care Stocks Moving In Friday's After-Marke...
4	BNC, SGBX: 12 Industrials Stocks Moving In Friday's Af...
5	CORZ, TDTH: 12 Information Technology Stocks Movin...
6	TEAM: Forecasting The Future: 9 Analyst...
7	PGNY: The Analyst Verdict: Progyny I...

Market Overview